A Phase Ib/II clinical trial of DDFPe as a radiosensitizer in glioblastoma
Although small, this trial shows that DDFPe used as a radiosensitizer appears to be safe and may provide some survival benefit.
TOLD MRI validation of reversal of tumor hypoxia in glioblastoma with a novel oxygen therapeutic
MRI scans indicated that oxygen breathing with DDFPe administration improved tumor oxygenation.
Reversal of Tumor hypoxia following intravenous delivery of DDFPe
DDFPe results in a significant increase in intra-tumoral oxygen tension for up to 45 minutes in our pancreatic xenograft model in mice.
Dynamic Oxygenation Measurements Using a Phosphorescent Coating Window Chamber Model
Intravenous injection of DDFPe in mice with tumors increases tumor oxygen levels.
Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with DDFPe
DDFPe administration in mice with pancreatic tumor xenografts resulted in increased tumor oxygen tension lasting up to two hours.
Radiosensitization of hypoxic tumor cells by DDFPe
DDFP plus carbogen appears to completely reverse the hypoxic cell radioresistance in this rat tumor model.